Draft monograph: Maridebart cafraglutide — submissions

Local reactions are omitted from the adverse-event table because the trials reported them separately

Having reviewed the draft on Maridebart cafraglutide, the respondent makes a single submission, on the view that one point put clearly is more use to the secretariat than six put together.

Injection-site reactions are reported in the source trials in a table of their own and do not appear in the systemic adverse-event table the monograph reproduces. The result is that the most common adverse experience of a subcutaneously administered compound is absent from the monograph’s adverse-event section.

The respondent proposes that local reactions be carried in the same table as systemic events, with the reporting convention of the source trial recorded in a footnote.

The route of administration studied is not the route in which the compound is supplied

The draft on Maridebart cafraglutide is a substantial document and the respondent has confined this submission to one matter.

The clinical section describes findings obtained by one route and the supply section describes presentations intended for another. A reader moving between the two sections will carry the effect estimate across the change without noticing that it has been carried, because nothing on the page marks the transition.

The respondent proposes that where the studied route and the supplied presentation differ, the difference be stated in the assessed-outcome table itself rather than in the supply section, on the ground that a reader consults the outcome table and does not always reach §8.

The respondent notes that submission 001 has already been made and confines this submission to a matter not covered by it.

Quantitative claims are reproduced without the method that produced them

The respondent submits on the draft monograph for Maridebart cafraglutide. The observation arises from teaching the material rather than from prescribing it.

Several figures in the draft are quoted from sources that determined them by different methods. A figure obtained by one determination and a figure obtained by another are not comparable, and the draft places them in the same sentence without distinguishing them.

The respondent, an analytical chemist, proposes that every quantitative claim carry the method that produced it at the point of use rather than in the reference.

Open-label extension data are presented alongside randomised data without distinction

The draft on Maridebart cafraglutide was read in full. The respondent notes at the outset that this class has an unusually deep randomised evidence base, and that a monograph on it is fairly judged against a higher standard than one on a compound with none.

Long-term figures in the clinical section come from open-label extensions in which every participant received the active compound and those who did not tolerate it had already withdrawn. They are printed in the same table as randomised comparisons and in the same typeface.

The respondent proposes that extension data be presented in a separate table, or at minimum in a separately labelled block, and that the surviving-population problem be stated once where it arises.

Registered trials that never reported are absent from the monograph

This submission concerns the draft on Maridebart cafraglutide. The respondent assesses incretin-class evidence for a national body and comments in a personal capacity.

The respondent states that the trial list appears to be drawn from published reports, and that registered trials which completed without a report are therefore invisible. The proportion of a programme that never reported is itself a finding about the evidence base.

The respondent proposes that every registered trial of the compound be listed, with its reporting status, whether or not a report exists.

The cardiovascular result is reported without the population that generated it

The respondent read the draft on Maridebart cafraglutide alongside the approved labelling for the class, and submits on one matter arising.

The cardiovascular outcome trials in this class enrolled populations selected for established disease or for high risk. The relative risk reduction is reproduced in the monograph without that selection, and a reader will apply it to a person at ordinary risk, where the absolute benefit is a fraction of the figure shown.

The respondent proposes that the absolute event rates in both arms be printed beside every relative estimate.

The indication table mixes approved indications with uses for which the compound is merely supplied

The respondent has read the draft monograph on Maridebart cafraglutide against a caseload in which incretin analogues are prescribed daily.

The indication table lists indications in a single sequence. Some are approved by a competent authority, some are the subject of trials that have not reported, and some are uses observed in supply with no trial evidence at all.

The respondent states that the three categories should not share a table without being distinguished in it.

The monograph does not tell a reader that a stated mass may be substantially counter-ion and water

This submission addresses the draft monograph on Maridebart cafraglutide. The respondent went through the document twice, once as a specialist and once as a reader arriving without the background.

The draft quotes vial contents in milligrams without stating whether the figure refers to peptide content or to total solids. For an acetate or trifluoroacetate salt of a peptide, the difference between the two can exceed a fifth of the stated mass.

The respondent, an analytical chemist, states that this is the single most consequential misreading in the field and that a monograph that does not address it directly is leaving the reader to discover it.

The absence of a rare harm in the trial set is presented as reassurance

This is a submission on the draft covering Maridebart cafraglutide, from a respondent whose work is with the people taking compounds of this class rather than with the trials that produced them.

The draft states that a specific serious event was not observed in the contributing trials. The respondent states that trials of the size conducted here could not have detected an event at the frequency in question, and that reporting the absence without that arithmetic converts an uninformative result into a reassuring one.

The respondent proposes that the detectable frequency be stated wherever the absence of an event is reported.